Concepts (69)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Temperament | 1 | 2021 | 36 | 0.710 |
Why?
|
| Mental Disorders | 4 | 2014 | 377 | 0.690 |
Why?
|
| Disasters | 1 | 2021 | 74 | 0.660 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 188 | 0.630 |
Why?
|
| Mothers | 1 | 2021 | 212 | 0.610 |
Why?
|
| Fear | 3 | 2014 | 271 | 0.390 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 37 | 0.330 |
Why?
|
| Serotonin Syndrome | 1 | 2009 | 1 | 0.300 |
Why?
|
| Depression | 2 | 2009 | 837 | 0.300 |
Why?
|
| Anxiety Disorders | 2 | 2009 | 319 | 0.290 |
Why?
|
| Complementary Therapies | 1 | 2009 | 51 | 0.290 |
Why?
|
| Stress, Psychological | 1 | 2014 | 641 | 0.280 |
Why?
|
| Schizophrenia | 1 | 2009 | 91 | 0.280 |
Why?
|
| Extinction, Psychological | 1 | 2009 | 103 | 0.270 |
Why?
|
| Caregivers | 1 | 2009 | 195 | 0.250 |
Why?
|
| Poverty | 1 | 2009 | 395 | 0.240 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2024 | 26 | 0.230 |
Why?
|
| Asthma | 1 | 2009 | 410 | 0.220 |
Why?
|
| Losartan | 1 | 2024 | 35 | 0.220 |
Why?
|
| Fluorescent Dyes | 1 | 2024 | 182 | 0.210 |
Why?
|
| Biology | 1 | 2023 | 20 | 0.200 |
Why?
|
| Disability Evaluation | 1 | 2003 | 74 | 0.200 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2022 | 19 | 0.190 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2003 | 280 | 0.190 |
Why?
|
| Personality Development | 1 | 2021 | 8 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 959 | 0.180 |
Why?
|
| Influenza, Human | 1 | 2022 | 90 | 0.180 |
Why?
|
| Zebrafish | 1 | 2022 | 146 | 0.170 |
Why?
|
| Attitude | 1 | 2021 | 108 | 0.170 |
Why?
|
| Child Development | 1 | 2021 | 95 | 0.170 |
Why?
|
| Child | 2 | 2021 | 3381 | 0.140 |
Why?
|
| Humans | 10 | 2024 | 42163 | 0.140 |
Why?
|
| Infant | 1 | 2021 | 1143 | 0.140 |
Why?
|
| Puerto Rico | 4 | 2022 | 1376 | 0.140 |
Why?
|
| Female | 6 | 2022 | 24018 | 0.130 |
Why?
|
| Pregnancy | 1 | 2021 | 1737 | 0.120 |
Why?
|
| Ligands | 2 | 2024 | 387 | 0.090 |
Why?
|
| Internet | 1 | 2010 | 234 | 0.070 |
Why?
|
| Morbidity | 1 | 2009 | 97 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2009 | 79 | 0.070 |
Why?
|
| Adolescent | 2 | 2010 | 5950 | 0.070 |
Why?
|
| Comorbidity | 1 | 2010 | 725 | 0.070 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 547 | 0.070 |
Why?
|
| Self Efficacy | 1 | 2009 | 211 | 0.070 |
Why?
|
| Male | 4 | 2024 | 22779 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2009 | 179 | 0.070 |
Why?
|
| Prevalence | 1 | 2010 | 1597 | 0.060 |
Why?
|
| Hospitalization | 1 | 2009 | 482 | 0.060 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2024 | 10 | 0.060 |
Why?
|
| Receptors, Angiotensin | 1 | 2024 | 15 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2024 | 37 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2009 | 1516 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2009 | 1586 | 0.050 |
Why?
|
| Quality of Life | 1 | 2009 | 599 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2024 | 103 | 0.050 |
Why?
|
| Translations | 1 | 2003 | 7 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2024 | 491 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2022 | 54 | 0.050 |
Why?
|
| Language | 1 | 2003 | 181 | 0.040 |
Why?
|
| Risk Factors | 1 | 2009 | 3942 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2022 | 173 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 1054 | 0.040 |
Why?
|
| Animals | 3 | 2024 | 16695 | 0.040 |
Why?
|
| Adult | 2 | 2022 | 13458 | 0.030 |
Why?
|
| Young Adult | 1 | 2022 | 4936 | 0.020 |
Why?
|
| Aged | 1 | 2003 | 7982 | 0.020 |
Why?
|
| Middle Aged | 1 | 2003 | 11819 | 0.020 |
Why?
|
| Psychiatry | 1 | 2007 | 35 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2007 | 467 | 0.010 |
Why?
|